Ocedurenone

Ocedurenone
Clinical data
Other namesKBP-5074
Legal status
Legal status
  • Investigational
Identifiers
  • 4-[(3S,3aR)-3-Cyclopentyl-7-(4-hydroxypiperidine-1-carbonyl)-3,3a,4,5-tetrahydropyrazolo[3,4-f]quinolin-2-yl]-2-chlorobenzonitrile
CAS Number
PubChem CID
UNII
Chemical and physical data
FormulaC28H30ClN5O2
Molar mass504.03 g·mol−1

Ocedurenone, formerly known as KBP-5074,[1] is a nonsteroidal, selective mineralocorticoid receptor antagonist that is being developed to treat hypertension in patients with chronic kidney disease with less risk of hyperkalemia than existing treatments.[2][3] In 2023, KPB Biosciences entered into talks to sell the drug to Novo Nordisk for USD$1.3 billion. It is a small molecule drug administered orally and is in a Phase III trial that is scheduled to complete in 2024.[4][5]

References

  1. ^ "Ocedurenone: A Novel Therapy for Uncontrolled Hypertension in Advanced Chronic Kidney Disease". Nephrology. 16 March 2023. Retrieved 4 November 2023.
  2. ^ Pitt, Bertram; Jaisser, Frederic; Bakris, George (October 2021). "An evaluation of KBP-5074 in advanced chronic kidney disease with uncontrolled hypertension". Expert Opinion on Investigational Drugs. 30 (10): 1017–1023. doi:10.1080/13543784.2021.1985462. ISSN 1744-7658.
  3. ^ Bakris, George; Pergola, Pablo E.; Delgado, Belkis; Genov, Diyan; Doliashvili, Tamar; Vo, Nam; Yang, Y. Fred; McCabe, James; Benn, Vincent; Pitt, Bertram (July 2021). "Effect of KBP-5074 on Blood Pressure in Advanced Chronic Kidney Disease: Results of the BLOCK-CKD Study". Hypertension. 78 (1): 74–81. doi:10.1161/HYPERTENSIONAHA.121.17073. PMC 8189259.
  4. ^ "Novo in $1.3B Deal Buys Late-Stage Hypertension Drug from Singapore Biotech". BioSpace. Retrieved 4 November 2023.
  5. ^ "Novo Nordisk in $1.3 bln deal to buy hypertension drug". Reuters. 16 October 2023. Retrieved 4 November 2023.


Stub icon

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.